Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CALT
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Calliditas Therapeutics
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.08B
- Ent value
- 1.92B
- Price/Sales
- 0.67
- Price/Book
- 10.12
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 6.33
- PEG
- -
- EPS growth
- 11.28%
- 1 year return
- 115.29%
- 3 year return
- 21.29%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
CALT does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 23.76 |
| EV to EBITDA | 42.29 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.67 |
| Price to Book | 10.12 |
| EV to Sales | 1.20 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 27.02M |
| EPS (TTM) | -8.95 |
| FCF per share (TTM) | -0.68 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.60B |
| Gross profit (TTM) | 1.50B |
| Operating income (TTM) | -368.18M |
| Net income (TTM) | -480.36M |
| EPS (TTM) | -8.95 |
| EPS (1y forward) | 6.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 93.46% |
| Operating margin (TTM) | -22.99% |
| Profit margin (TTM) | -30.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 797.28M |
| Net receivables | 222.59M |
| Total current assets | 1.15B |
| Goodwill | 47.81M |
| Intangible assets | 423.86M |
| Property, plant and equipment | 59.36M |
| Total assets | 1.75B |
| Accounts payable | 151.01M |
| Short/Current long term debt | 1.01B |
| Total current liabilities | 429.78M |
| Total liabilities | 1.64B |
| Shareholder's equity | 106.79M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -244.93M |
| Capital expenditures (TTM) | 12.79M |
| Free cash flow (TTM) | -36.67M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -449.82% |
| Return on Assets | -27.49% |
| Return on Invested Capital | -44.10% |
| Cash Return on Invested Capital | -3.37% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| CALT | S&P500 | |
| Current price drop from All-time high | -3.73% | -0.14% |
| Highest price drop | -68.62% | -56.47% |
| Date of highest drop | 20 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -34.45% | -10.99% |
| Avg time to new high | 54 days | 12 days |
| Max time to new high | 877 days | 1805 days |
COMPANY DETAILS
Marketcap
1.08B
Marketcap category
Small-cap
Description
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
Employees
222
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner